Last reviewed · How we verify
Universidad Peruana Cayetano Heredia — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
3 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| "Raltegravir" and "Zidovudine" | "Raltegravir" and "Zidovudine" | marketed | Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitor) | HIV integrase (raltegravir); HIV reverse transcriptase (zidovudine) | Infectious Disease / Virology |
Therapeutic area mix
- Infectious Disease / Virology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Universidad Peruana Cayetano Heredia:
- Universidad Peruana Cayetano Heredia pipeline updates — RSS
- Universidad Peruana Cayetano Heredia pipeline updates — Atom
- Universidad Peruana Cayetano Heredia pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Universidad Peruana Cayetano Heredia — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universidad-peruana-cayetano-heredia. Accessed 2026-05-16.